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Introduction
Neuromyelitis optica spectrum disorder (NMO-SD) has a 
worldwide prevalence of 0.5–10 persons per 100,000 popu-
lation. It is characterised by inflammatory events centred 
on the optic nerve and spinal cord, often with poor recovery 
and subsequent residual disability. More than two-thirds of 
patients with NMO-SD have serum antibodies to the water 
channel protein aquaporin-4 (AQP4-immunoglobulin G 
[IgG]), which is implicated in the pathophysiology of NMO-
SD. Others are seronegative or have serum antibodies to 
myelin oligodendrocyte glycoprotein. Diagnostic criteria 
depend on AQP4-IgG antibody status: those with sero-
positivity can have involvement of almost any CNS region, 
whereas those who are seronegative must have experienced 
at least one of either an optic neuritis, longitudinally exten-
sive transverse myelitis, or area postrema syndrome with 
associated MRI lesions. Treatment of NMO-SD to date has 
largely been based on observational studies, case reports 
and retrospective analyses, and has included empiric use 
of off-label treatments such as rituximab, azathioprine and 
mycophenolate mofetil. However, with the recent comple-
tion of phase 3 clinical trials, an improved evidence base for 
current treatments and novel treatment options for NMO-SD 
are now emerging. Three clinical trials evaluate the mono-
clonal antibodies rituximab, satralizumab and eculizumab, 
versus placebo in the treatment of NMO-SD, and are dis-
cussed below.
Safety and efficacy of rituximab 
in neuromyelitis optica spectrum disorders 
(RIN‑1 study): a multicentre, randomised, 
double‑blind, placebo‑controlled trial
Rituximab targets CD20 (a surface antigen primarily 
expressed on B lymphocytes) and causes B cell depletion. In 
this trial, NMO-SD patients with current or previous AQP4 
seropositivity, and an Expanded Disability Status Scale 
(EDSS) score of 7.0 or less, were randomly assigned (1:1) 
treatment with rituximab (intravenous [IV], every week for 
4-weeks and then 6-month interval dosing; n = 19) or pla-
cebo (matched administration; n = 19). To reduce excessive 
risk of relapse, patients were also treated with 2-months of 
a fixed dose of oral steroid, which was then slowly reduced. 
The primary outcome was time to first relapse in the 
72-week study period. No relapses occurred in the rituximab 
group, whereas seven (37%) relapses occurred in the placebo 
group (p = 0.0058). The EDSS score worsened in those who 
had relapses; however, the average change in EDSS score 
was similar between the two study groups. Conversely, the 
authors report that the average change in total quantification 
of optic nerve and spinal cord impairment (QOSI) score was 
significantly higher in the placebo group. 37% of patients 
had an infusion reaction in the rituximab group, compared 
to none in the placebo group (p = 0.008). Otherwise adverse 
events did not differ significantly between the groups. One 
patient in the rituximab group discontinued secondary to an 
adverse event. There were no cases of progressive multifocal 
leukoencephalopathy.
Comment. As one might have expected, this trial reports 
positive findings for the use of rituximab for relapse pre-
vention in NMO-SD patients who are AQP4 seropositive. 
A limitation of this trial is the small sample size, which the 
authors state does not allow for an accurate quantification of 
the magnitude of risk reduction attributed to rituximab. Fur-
thermore, the study only included patients who were adults, 
of Japanese ethnic origin, and who had AQP4 seropositiv-
ity, limiting the generalisability of the results. The power of 
the trial may have been reduced by the use of concomitant 
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steroids, and the difference in annualised relapse rate (ARR) 
in the 2 years pre-enrolment between the rituximab group 
(1.4 relapses per person-year) and the placebo group (0.7 
relapses per person-year), could have resulted in an under-
estimation of the efficacy of rituximab. Despite its efficacy 
in relapse prevention, it is interesting that there was no sig-
nificant change in the EDSS score between both groups, pos-
sibly due to the use of concomitant steroids. They did report 
a significant change in the QOSI; however, this score is not 
widely used and its psychometric properties have not been 
studied in NMO-SD. Larger trials would clearly be of value 
and further studies are warranted to assess the efficacy of 
rituximab in AQP4 seronegative patients.
Tahara M et al. (2020) Safety and efficacy of rituximab 
in neuromyelitis optica spectrum disorders (RIN-1 study): a 
multicentre, randomised, double-blind, placebo-controlled 
trial. Lancet Neurol 19(4):298–306.
Safety and efficacy of satralizumab 
monotherapy in neuromyelitis optica 
spectrum disorder: a randomised, 
double‑blind, multicentre, 
placebo‑controlled phase 3 trial
Satralizumab binds to IL 6 receptors, inhibiting the IL 6 
signalling pathways involved in inflammation. In this trial, 
patients with AQP4-positive or AQP4-negative NMO-SD, 
and an EDSS score of 6.5 or less, were randomly assigned 
(2:1) treatment with satralizumab (subcutaneous, every 
2-weeks for 4 weeks and every 4-weeks thereafter; n = 63) 
or placebo (matched administration; n = 32). Steroid use 
was only allowed for the acute treatment of relapses. As 
concomitant immunosuppressants were prohibited, unequal 
randomisation was used to minimise risk of harm of no 
treatment. The primary outcome was time to first protocol-
defined relapse in the double-blind period (1·5 years after 
the random assignment of the last enrolled patient). 30% 
of the satralizumab group had a protocol-defined relapse, 
compared to 50% of the placebo group (p = 0.018). Fur-
thermore, those in the placebo group had a shorter time 
to relapse. However, when analysed by AQP4 serostatus, 
the results differed. In the seropositive cohort, 22% in the 
satralizumab group had a protocol-defined relapse, versus 
57% in the placebo group. Conversely in the seronegative 
cohort, 46% in the satralizumab group experienced a pro-
tocol-defined relapse, versus 33% in the placebo group. For 
all patients, mean change in EDSS score at week 24 was 
− 0·34 for the satralizumab group and − 0·17 for the placebo 
group. The overall rate of infections was similar between the 
two groups, and no opportunistic infections were reported 
in those treated with satralizumab. Severe adverse events 
were higher in the satralizumab group (32·1 events per 100 
patient-years; versus 9·9 events per 100 patient-years in the 
placebo group). The authors state that 73% were considered 
unrelated to the study treatment, however one (pneumonia) 
led to discontinuation of the study drug.
Comment. This trial demonstrates encouraging results for 
the use of satralizumab in relapse prevention for patients 
with NMO-SD and AQP4 seropositivity. The evidence 
however was insufficient to support use for seronegative 
patients. In contrast to the rituximab trial, patients in this 
trial were only eligible if they had a clinical relapse in the 
last 12-months, thereby potentially inherently selecting those 
with a higher disease activity. Furthermore, the prohibition 
of concomitant treatments allowed for more definite clar-
ification of the effect of satralizumab in the treatment of 
NMO-SD. Other limitations of this trial include small group 
numbers, low relapse numbers, and inclusion of adults only.
Traboulsee A et al. (2020) Safety and efficacy of satrali-
zumab monotherapy in neuromyelitis optica spectrum dis-
order: a randomised, double-blind, multicentre, placebo-
controlled phase 3 trial. Lancet Neurol 19(5):402–412.
Eculizumab in Aquaporin‑4–positive 
neuromyelitis optica spectrum disorder
Eculizumab inhibits the terminal complement protein C5, 
impeding the complement cascade at this point. In this phase 
3 double-blind trial, patients with NMO-SD and AQP4 sero-
positivity, with an EDSS score of 7.0 or less, were randomly 
assigned (2:1) treatment with eculizumab (IV, every week 
for the first four doses, followed by every 2-weeks; n = 96) 
or placebo (matched administration; n = 47). If patients 
were already receiving immunosuppressive therapies for 
relapse prevention, they were still eligible for inclusion, as 
long as they were on a stable drug regimen; however, this 
excluded treatment with rituximab or mitoxantrone in the 
last 3-months, prednisone in doses greater than 20 mg/day or 
equivalent and IVIg in the previous 3-weeks. Crucially, the 
study also excluded anyone with unresolved meningococcal 
disease, or other infections considered to be clinically signif-
icant or not treated with appropriate antibiotics, and patients 
received a vaccination against Neisseria meningitidis 
before receiving a study agent. This is because eculizumab 
increases the risk of infection with encapsulated organisms, 
and fatalities from meningococcal infections have previously 
been reported. The primary end point of first adjudicated 
relapse occurred in 3% of the eculizumab group and 43% of 
the placebo group (p < 0.001). In those not receiving con-
comitant immunosuppressive therapy (approximately one-
quarter of patients), no adjudicated relapses occurred in the 
eculizumab group (n = 21), whereas 54% occurred in the pla-
cebo group (n = 13). There was a significantly lower adjudi-
cated ARR in the eculizumab group compared to the placebo 
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group. The difference between groups in change in EDSS 
score was not significant. In the eculizumab group, rates of 
upper respiratory tract infection were higher; furthermore, 
one patient, who was also receiving azathioprine, died from 
a pulmonary empyema which was deemed probably related 
to the trial agent. No cases of meningococcal infection were 
reported, and no patients discontinued eculizumab due to 
adverse events.
Comment. Finally, this trial similarly shows promising 
results for the use of eculizumab in relapse prevention in 
NMO-SD AQP4-positive patients, although it found no sig-
nificant between-group difference in measures of disabil-
ity progression. Again, in contrast to the previous trials, it 
should be noted that patients were only eligible for inclu-
sion if they had at least two relapses in the last 12-months, 
or three relapses in the previous 24-months, one of which 
had to occur in the previous year, raising the possibility of 
selection bias for those with higher disease activity. Addi-
tionally, it is important to highlight that each trial used dif-
ferent criteria to define a relapse; in particular the rituximab 
study required objective abnormalities on MRI. The death 
of a study participant in the eculizumab trial is an important 
reminder of the risks that immunosuppressive treatments 
carry. Limitations of this trial include the exclusion of AQP4 
seronegative patients and the inclusion of adults only. Fur-
thermore, the power of the trial was blunted due to earlier 
termination than originally planned, and the trial allowed the 
use of concomitant immunosuppressive therapies in around 
three-quarters of patients.
Pittock SJ et al. (2019) Eculizumab in aquaporin-4–posi-
tive neuromyelitis optica spectrum disorder. N Engl J Med 
381(7):614–625.
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